Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tezampanel - Proniras

Next Previous
Drug Profile

Tezampanel - Proniras

Alternative Names: LY 293558; NGX 424; PRN-001-01

Latest Information Update: 28 Oct 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Indiana University School of Medicine; Proniras Corporation; Raptor Pharmaceutical Corp
  • Class Analgesics; Antiepileptic drugs; Antimigraines; Antithrombotics; Drug withdrawal therapies; Isoquinolines; Tetrazoles
  • Mechanism of Action AMPA receptor antagonists; Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Opioid-related disorders
  • No development reported Seizures
  • Discontinued Migraine; Neuromuscular disorders; Thrombosis

Most Recent Events

  • 28 Oct 2024 No recent reports of development identified for preclinical development in Opioid-related-disorders in USA (Parenteral)
  • 16 Oct 2024 Phase-I clinical trials in Opioid-related disorders in USA (IV) (NCT06538558)
  • 06 Aug 2024 Proniras Corporation plans a phase-I trial for Opioid-related disorders in October 2024 (IV), (NCT06538558)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top